Oncopeptides AB (publ) (STO:ONCO)
Sweden
· Delayed Price · Currency is SEK 5.35
+0.10 (1.90%)
At close: Dec 5, 2025
Oncopeptides AB Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Cash & Equivalents | 147.92 | 178.54 | 173.41 | 344.52 | 362.19 | 840.26 | Upgrade
|
| Short-Term Investments | - | - | 0.03 | 0.35 | 2.11 | 12.23 | Upgrade
|
| Cash & Short-Term Investments | 147.92 | 178.54 | 173.44 | 344.86 | 364.3 | 852.48 | Upgrade
|
| Cash Growth | -40.84% | 2.94% | -49.71% | -5.33% | -57.27% | -7.96% | Upgrade
|
| Accounts Receivable | 35.02 | 7.29 | 2.19 | 0.67 | 11.87 | - | Upgrade
|
| Other Receivables | - | 6.24 | 15.68 | 16.25 | 24.01 | 11 | Upgrade
|
| Receivables | 35.02 | 13.53 | 17.87 | 16.92 | 35.89 | 11 | Upgrade
|
| Inventory | 8.43 | 4.37 | 2.43 | - | - | 8.67 | Upgrade
|
| Prepaid Expenses | - | 6.19 | 5.43 | 1.71 | 7.42 | 8.96 | Upgrade
|
| Other Current Assets | 0 | 9.96 | 3.73 | 0.54 | 4.76 | 13.69 | Upgrade
|
| Total Current Assets | 191.37 | 217.08 | 202.9 | 364.03 | 412.37 | 894.8 | Upgrade
|
| Property, Plant & Equipment | 19.91 | 27.11 | 34.63 | 20.44 | 24.74 | 38.33 | Upgrade
|
| Other Intangible Assets | - | - | - | - | 1.41 | 1.83 | Upgrade
|
| Long-Term Deferred Tax Assets | - | - | - | - | - | 8.18 | Upgrade
|
| Other Long-Term Assets | - | -0 | 0.85 | 0.85 | 0.85 | 3.62 | Upgrade
|
| Total Assets | 211.28 | 244.19 | 238.38 | 385.32 | 439.38 | 946.76 | Upgrade
|
| Accounts Payable | 12.24 | 18.17 | 15.03 | 28.22 | 35.7 | 136.14 | Upgrade
|
| Accrued Expenses | - | 15.12 | 20.38 | 17.24 | 36.61 | 150.27 | Upgrade
|
| Current Portion of Leases | - | 7.27 | 5.13 | 6 | 10.99 | 12.43 | Upgrade
|
| Current Income Taxes Payable | - | 1.73 | 0.58 | 0.3 | 0.05 | 3.05 | Upgrade
|
| Current Unearned Revenue | - | 0.07 | 0.5 | - | - | - | Upgrade
|
| Other Current Liabilities | 43.74 | 4.66 | 3.32 | 33.91 | 141.94 | 52.52 | Upgrade
|
| Total Current Liabilities | 55.97 | 51.36 | 44.93 | 85.67 | 225.29 | 354.4 | Upgrade
|
| Long-Term Debt | 126.2 | 121.89 | 106.49 | - | - | - | Upgrade
|
| Long-Term Leases | 22.57 | 12.55 | 19.67 | - | 3.21 | 6.93 | Upgrade
|
| Other Long-Term Liabilities | 0 | 4.11 | 10.51 | 5.36 | 0.01 | 8.53 | Upgrade
|
| Total Liabilities | 204.74 | 189.91 | 181.6 | 91.03 | 228.51 | 369.86 | Upgrade
|
| Common Stock | 23.91 | 23.91 | 10.51 | 10.48 | 8.37 | 7.55 | Upgrade
|
| Additional Paid-In Capital | - | 5,684 | 5,414 | 5,403 | 4,982 | 3,919 | Upgrade
|
| Retained Earnings | - | -5,651 | -5,366 | -5,116 | -4,778 | -3,348 | Upgrade
|
| Comprehensive Income & Other | -17.37 | -2.84 | -2.2 | -2.3 | -0.92 | -1.54 | Upgrade
|
| Shareholders' Equity | 6.54 | 54.29 | 56.78 | 294.29 | 210.87 | 576.9 | Upgrade
|
| Total Liabilities & Equity | 211.28 | 244.19 | 238.38 | 385.32 | 439.38 | 946.76 | Upgrade
|
| Total Debt | 148.77 | 141.72 | 131.29 | 6 | 14.19 | 19.36 | Upgrade
|
| Net Cash (Debt) | -0.85 | 36.82 | 42.15 | 338.86 | 350.11 | 833.13 | Upgrade
|
| Net Cash Growth | - | -12.65% | -87.56% | -3.21% | -57.98% | -8.58% | Upgrade
|
| Net Cash Per Share | -0.00 | 0.22 | 0.47 | 4.12 | 4.65 | 13.36 | Upgrade
|
| Filing Date Shares Outstanding | 272.71 | 215.19 | 94.6 | 94.31 | 75.29 | 67.94 | Upgrade
|
| Total Common Shares Outstanding | 272.71 | 215.19 | 94.6 | 94.31 | 75.29 | 67.94 | Upgrade
|
| Working Capital | 135.39 | 165.73 | 157.97 | 278.36 | 187.08 | 540.4 | Upgrade
|
| Book Value Per Share | 0.02 | 0.25 | 0.60 | 3.12 | 2.80 | 8.49 | Upgrade
|
| Tangible Book Value | 6.54 | 54.29 | 56.78 | 294.29 | 209.46 | 575.07 | Upgrade
|
| Tangible Book Value Per Share | 0.02 | 0.25 | 0.60 | 3.12 | 2.78 | 8.46 | Upgrade
|
| Machinery | - | 16.46 | 16.1 | 15.99 | 14.42 | 19.94 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.